Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures

Practical Radiation Oncology

Volumn 8, Issue 5, 2018, Pages 307-316

  Lee, Daniel J ^a   Barocas, Daniel A ^a   Zhao, Zhiguo ^a   Huang, Li Ching ^a   Koyama, Tatsuki ^a   Resnick, Matthew J ^a   Conwill, Ralph ^b   McCollum, Dan ^b   Cooperberg, Matthew R ^c   Goodman, Michael ^d   Greenfield, Sheldon ^e   Hamilton, Ann S ^f   Hashibe, Mia ^g   Kaplan, Sherrie H ^h   Paddock, Lisa E ⁱ   Stroup, Antoinette M ⁱ   Wu, Xiao Cheng ^j   Penson, David F ^k   Hoffman, Karen E ^l  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^j LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^k Veterans Administration Tennessee Valley Health Care System   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CAUCASIAN; CONTROLLED STUDY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HISPANIC; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MINORITY GROUP; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROTOCOL COMPLIANCE; RADIATION DOSE; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; UNITED STATES; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; HEALTH CARE SURVEY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROSTATE; PROSTATE TUMOR; QUALITY CONTROL; RADIATION ONCOLOGY; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; STANDARDS; STATISTICS AND NUMERICAL DATA;

AGED; BRACHYTHERAPY; DOSE FRACTIONATION; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROSTATE; PROSTATIC NEOPLASMS; QUALITY CONTROL; RADIATION ONCOLOGY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; UNITED STATES;

EID: 85048310552     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2018.04.009     Document Type: Article

References (50)

1. Choudhry, NK, Rosenthal, MB, Milstein, A, Assessing the evidence for value-based insurance design. Health Aff (Millwood) 29 (2010), 1988–1994.
2. Fisher, ES, Shortell, SM, Accountable care organizations: accountable for what, to whom, and how. JAMA 304 (2010), 1715–1716.
3. McGlynn, EA, Asch, SM, Adams, J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 348 (2003), 2635–2645.
4. Schmid, M, Meyer, CP, Reznor, G, et al. Racial differences in the surgical care of Medicare beneficiaries with localized prostate cancer. JAMA Oncol 2 (2016), 85–93.
5. Samuel, CA, Landrum, MB, McNeil, BJ, Bozeman, SR, Williams, CD, Keating, NL, Racial disparities in cancer care in the Veterans Affairs health care system and the role of site of care. Am J Public Health 104 (2014), S562–S571.
6. Mariotto, AB, Yabroff, KR, Shao, Y, Feuer, EJ, Brown, ML, Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103 (2011), 117–128.
7. Centers for Medicare and Medicaid Services, Quality Measures. Available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/index.html?redirect=/QualityMeasures/03_ElectronicSpecifications.asp. (Accessed 1 September 2017)
8. Albert, JM, Das, P, Quality indicators in radiation oncology. Int J Radiat Oncol Biol Phys 85 (2013), 904–911.
9. Zelefsky, MJ, Lee, WR, Zietman, A, et al. Evaluation of adherence to quality measures for prostate cancer radiotherapy in the United States: Results from the Quality Research in Radiation Oncology (QRRO) survey. Pract Radiat Oncol 3 (2013), 2–8.
10. Lehman, M, Hayden, AJ, Martin, JM, et al. FROGG high-risk prostate cancer workshop: Patterns of practice and literature review. Part I: Intact prostate. J Med Imaging Radiat Oncol 58 (2014), 257–265.
11. Webber, C, Brundage, MD, Siemens, DR, Groome, PA, Quality of care indicators and their related outcomes: A population-based study in prostate cancer patients treated with radiotherapy. Radiother Oncol 107 (2013), 358–365.
12. Brundage, M, Danielson, B, Pearcey, R, et al. A criterion-based audit of the technical quality of external beam radiotherapy for prostate cancer. Radiother Oncol 107 (2013), 339–345.
13. Lubeck, DP, Litwin, MS, Henning, JM, et al. The CaPSURE database: A methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 48 (1996), 773–777.
14. Barocas, DA, Chen, V, Cooperberg, M, et al. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: The CEASAR study. J Comp Eff Res 2 (2013), 445–460.
15. Litwin, MS, Greenfield, S, Elkin, EP, Lubeck, DP, Broering, JM, Kaplan, SH, Assessment of prognosis with the total illness burden index for prostate cancer: Aiding clinicians in treatment choice. Cancer 109 (2007), 1777–1783.
16. National Comprehensive Cancer Network, The NCCN Clinical Practice Guidelines in Oncology Prostate Cancer (Version 4.2011). Available at: http://www.nccn.org. (Accessed 12 September 2016)
17. Davis, BJ, Horwitz, EM, Lee, WR, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11 (2012), 6–19.
18. American Brachytherapy Society, Quality research in radiation oncology guidelines. Available at: http://www.qrro.org/Prostate_CPM.pdf Accessed September 12, 2016.
19. Penson, DF, Assessing the quality of prostate cancer care. Curr Opin Urol 18 (2008), 297–302.
20. Efstathiou, JA, Nassif, DS, McNutt, TR, et al. Practice-based evidence to evidence-based practice: Building the National Radiation Oncology Registry. J Oncol Pract 9 (2013), e90–e95.
21. D'Amico, AV, Whittington, R, Malkowicz, SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998), 969–974.
22. Harrell, F, Regression. Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression and Survival Analysis, 2nd ed., 2015, Springer-Verlag, New York, NY.
23. Stokes, WA, Kavanagh, BD, Raben, D, Pugh, TJ, Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis. Pract Radiat Oncol 7 (2017), 270–278.
24. Bilimoria, KY, Stewart, AK, Winchester, DP, Ko, CY, The National Cancer Data Base: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15 (2008), 683–690.
25. Halpern, JA, Sedrakyan, A, Hsu, WC, et al. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer 122 (2016), 2496–2504.
26. Peeters, ST, Heemsbergen, WD, Koper, PC, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006), 1990–1996.
27. Dearnaley, DP, Sydes, MR, Graham, JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007), 475–487.
28. Kuban, DA, Tucker, SL, Dong, L, et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008), 67–74.
29. Zietman, AL, DeSilvio, ML, Slater, JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005), 1233–1239.
30. Jones, CU, Hunt, D, McGowan, DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365 (2011), 107–118.
31. Wirth, MP, See, WA, McLeod, DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median follow up of 5.4 years. J Urol 172 (2004), 1865–1870.
32. Pommier, P, Chabaud, S, Lagrange, JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25 (2007), 5366–5373.
33. Lawton, CA, DeSilvio, M, Roach, M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007), 646–655.
34. Asbell, SO, Krall, JM, Pilepich, MV, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15 (1988), 1307–1316.
35. Pilepich, MV, Winter, K, Lawton, CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005), 1285–1290.
36. Hanks, GE, Pajak, TF, Porter, A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003), 3972–3978.
37. Bolla, M, Collette, L, Blank, L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002), 103–106.
38. Levine, GN, D'Amico, AV, Berger, P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121 (2010), 833–840.
39. Nanda, A, Chen, MH, Braccioforte, MH, Moran, BJ, D'Amico, AV, Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302 (2009), 866–873.
40. Tsai, HK, D'Amico, AV, Sadetsky, N, Chen, MH, Carroll, PR, Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007), 1516–1524.
41. Muralidhar, V, Catalano, PJ, Reznor, G, et al. Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer. J Natl Compr Cancer Netw 14 (2016), 421–428.
42. Dell'Oglio, P, Abou-Haidar, H, Leyh-Bannurah, SR, et al. Assessment of the rate of adherence to international guidelines for androgen deprivation therapy with external-beam radiation therapy: A population-based study. Eur Urol 70 (2016), 429–435.
43. Gross, CP, Smith, BD, Wolf, E, Andersen, M, Racial disparities in cancer therapy: Did the gap narrow between 1992 and 2002?. Cancer 112 (2008), 900–908.
44. Spencer, BA, Miller, DC, Litwin, MS, et al. Variations in quality of care for men with early-stage prostate cancer. J Clin Oncol 26 (2008), 3735–3742.
45. Ellis, SD, Blackard, B, Carpenter, WR, et al. Receipt of National Comprehensive Cancer Network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer 119 (2013), 2282–2290.
46. Dearnaley, D, Syndikus, I, Mossop, H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17 (2016), 1047–1060.
47. Incrocci, L, Wortel, RC, Alemayehu, WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17 (2016), 1061–1069.
48. Sathya, JR, Davis, IR, Julian, JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005), 1192–1199.
49. Hoskin, PJ, Rojas, AM, Bownes, PJ, Lowe, GJ, Ostler, PJ, Bryant, L, Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103 (2012), 217–222.
50. MacLean, CH, Louie, R, Shekelle, PG, et al. Comparison of administrative data and medical records to measure the quality of medical care provided to vulnerable older patients. Med Care 44 (2006), 141–148.